231 related articles for article (PubMed ID: 29050116)
61. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ
J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715
[TBL] [Abstract][Full Text] [Related]
62. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
63. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
65. Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia.
Carey ME; Hockenberry MJ; Moore IM; Hutter JJ; Krull KR; Pasvogel A; Kaemingk KL
J Pediatr Psychol; 2007 Mar; 32(2):189-93. PubMed ID: 16675716
[TBL] [Abstract][Full Text] [Related]
66. [Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia].
Luo GJ; Wang L; Hu GF; Li CB; Liu HX; Peng MT
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1973-1978. PubMed ID: 32629599
[No Abstract] [Full Text] [Related]
67. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen.
Kroll M; Kaupat-Bleckmann K; Mörickel A; Altenl J; Schewel DM; Stanullal M; Zimmermann M; Schrappe M; Cario G
Haematologica; 2020 Apr; 105(4):1013-1020. PubMed ID: 31371414
[TBL] [Abstract][Full Text] [Related]
68. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
69. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
70. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation.
Hill JM; Kornblith AB; Jones D; Freeman A; Holland JF; Glicksman AS; Boyett JM; Lenherr B; Brecher ML; Dubowy R; Kung F; Maurer H; Holland JC
Cancer; 1998 Jan; 82(1):208-18. PubMed ID: 9428499
[TBL] [Abstract][Full Text] [Related]
71. Acral erythema in children receiving high-dose methotrexate.
Millot F; Auriol F; Brecheteau P; Guilhot F
Pediatr Dermatol; 1999; 16(5):398-400. PubMed ID: 10571844
[TBL] [Abstract][Full Text] [Related]
72. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.
Thyss A; Suciu S; Bertrand Y; Mazingue F; Robert A; Vilmer E; Mechinaud F; Benoit Y; Brock P; Ferster A; Lutz P; Boutard P; Marguerite G; Plouvier E; Michel G; Plantaz D; Munzer M; Rialland X; Chantraine JM; Norton L; Solbu G; Philippe N; Otten J
J Clin Oncol; 1997 May; 15(5):1824-30. PubMed ID: 9164191
[TBL] [Abstract][Full Text] [Related]
73. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
74. CNS late-effects after ALL therapy in childhood. Part III: neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory.
Langer T; Martus P; Ottensmeier H; Hertzberg H; Beck JD; Meier W
Med Pediatr Oncol; 2002 May; 38(5):320-8. PubMed ID: 11979456
[TBL] [Abstract][Full Text] [Related]
75. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
[TBL] [Abstract][Full Text] [Related]
76. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
77. Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.
Xu W; Tang Y; Song H; Shi S; Yang S
J Pediatr Hematol Oncol; 2007 Oct; 29(10):688-93. PubMed ID: 17921849
[TBL] [Abstract][Full Text] [Related]
78. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
[TBL] [Abstract][Full Text] [Related]
79. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
80. Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity.
Kubota M; Nakata R; Adachi S; Watanabe K; Heike T; Takeshita Y; Shima M
Leuk Lymphoma; 2014 Jul; 55(7):1591-5. PubMed ID: 24090503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
